laris Lifesciences, one of the largest manufactuers of sterile injectibles, finally heaves a sigh of relief as its initial public offering hits the capital markets on November 24 at a price band of Rs. 278-293 per share. The drugmaker plans to utilise the proceeds of Rs. 300 crore to fund expansions.
